- Home
- SVII vs AGEN Comparison
SVII vs AGEN Comparison
Compare SVII & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- AGEN
- Stock Information
- Founded
- SVII 2021
- AGEN 1994
- Country
- SVII United States
- AGEN United States
- Employees
- SVII N/A
- AGEN N/A
- Industry
- SVII Blank Checks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVII Finance
- AGEN Health Care
- Exchange
- SVII Nasdaq
- AGEN Nasdaq
- Market Cap
- SVII 111.1M
- AGEN 96.2M
- IPO Year
- SVII 2022
- AGEN 2000
- Fundamental
- Price
- SVII $11.22
- AGEN $2.83
- Analyst Decision
- SVII
- AGEN Buy
- Analyst Count
- SVII 0
- AGEN 3
- Target Price
- SVII N/A
- AGEN $10.50
- AVG Volume (30 Days)
- SVII 74.3K
- AGEN 566.5K
- Earning Date
- SVII 01-01-0001
- AGEN 11-12-2024
- Dividend Yield
- SVII N/A
- AGEN N/A
- EPS Growth
- SVII 13.16
- AGEN N/A
- EPS
- SVII 0.36
- AGEN N/A
- Revenue
- SVII N/A
- AGEN $160,427,000.00
- Revenue This Year
- SVII N/A
- AGEN N/A
- Revenue Next Year
- SVII N/A
- AGEN $36.13
- P/E Ratio
- SVII $31.11
- AGEN N/A
- Revenue Growth
- SVII N/A
- AGEN 59.00
- 52 Week Low
- SVII $10.81
- AGEN $2.50
- 52 Week High
- SVII $11.70
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- SVII 39.53
- AGEN 39.40
- Support Level
- SVII $11.20
- AGEN $2.65
- Resistance Level
- SVII $11.24
- AGEN $3.85
- Average True Range (ATR)
- SVII 0.01
- AGEN 0.29
- MACD
- SVII 0.01
- AGEN -0.02
- Stochastic Oscillator
- SVII 40.00
- AGEN 15.00
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).